Middle East & Africa Coagulation Analyzers Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Clinical Laboratory Analyzers and Point-of-care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotti

Middle East & Africa Coagulation Analyzers Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Clinical Laboratory Analyzers and Point-of-care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimer Testing, Platelet Function Tests, Anti-Factor XA Tests, Heparin and Protamine Dose Response Tests for ACT, and Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Other Technologies), and End Users (Hospitals, Clinical Laboratories, Point-of-Care Testing, and Others)

The Middle East & Africa coagulation analyzers market is expected to grow from US$ 193.71 million in 2022 to US$ 259.47 million by 2028. It is estimated to grow at a CAGR of 5.0% from 2022 to 2028.

Development of Point-of-Care (POC) Coagulation Analyzers is Driving the Middle East & Africa Coagulation Analyzers Market

A rapid, reliable assessment of hemostasis is essential for patients with trauma or other bleeding problems. Due to the requirements of sample preparation and the analytical process, routine coagulation assays cannot visualize the process of clot formation, and their results are obtained only after 30-90 minutes. Point-of-care (POC) devices such as viscoelastic coagulation tests, platelet function tests, blood gas analysis, and other coagulometers are available for assessment of hemostasis. A POC measurement tool can be used both inside and outside the hospital as a decision-making and management tool. When time is paramount, POC analyzers provide immediate, actionable results in emergency rooms, coronary care units, surgery, and procedure suites. In addition to outpatient clinics and physicians' offices, these devices can assist with patient management in pharmacies, care centers, and patients' homes. POC coagulation analyzers offer timely results without compromising diagnostic quality control provided by central labs. In POC testing, it is important to provide fast results, along with accuracy and quality assurance.

In 2021, Siemens Healthineers launched fully automated CN-3000 and CN-6000 systems, which are mid- and high-volume handheld POC coagulation testing devices. Siemens Healthineers' Xprecia Stride Coagulation Analyser was cleared by the FDA as a POC coagulation analyzers device. The device has demonstrated PT/INR (prothrombin time/international normalized ratio) testing performance equivalence to Roche CoaguChek XS.

Thus, the growing development of POC coagulation analyzer is likely to propel the Middle East & Africa coagulation analyzers market growth during the forecast period.

Middle East & Africa Coagulation Analyzers Market Overview

The Middle East & Africa consists of three major countries, namely the UAE, Saudi Arabia, and South Africa. The market is expected to have significant growth opportunities owing to the rising development in the medical facilities, increasing prevalence of blood disorders, and rise in incidences of atrial fibrillation and other cardiovascular diseases.

Saudi Arabia is among the well-established country in the Middle East region. It is accounted for as the richest economies and is developing in terms of the healthcare sector rapidly. However, the country is majorly dependent on imports for medical device products. The rising incidences of chronic and acute diseases such as cardiovascular disorders have led to increasing demand for coagulation analyzers in the country. Coronary heart disease constitutes one of the main health problems in Saudi Arabia, constituting the third most common cause of hospital-based mortality, second to accident and senility. According to Archives of Pharmacy Practice, the prevalence of coronary heart disease is at 6%, stipulating a high burden of disease and associated risk factors. Similarly, the increasing prevalence of cardiovascular diseases in the UAE will likely to increase the demand coagulation analyzers. According to a study conducted by Cleveland Clinic Abu Dhabi, more than half of the residents in UAE have been affected by heart disease during their lifespan. Cardiovascular disease is the prime cause of death in the UAE, with symptoms in patients often occurring a decade earlier than their counterparts in other developed nations. According to an article published by PLOS ONE, CVD contributes to 40% of all deaths. Its incidence is increasing in young adults mainly because of an increase in the burden of its known risk factors such as abdominal obesity (71.5%), dyslipidemia (74.0%), hypertension (43.0%), and diabetes (32.4%).

Also, rising prevalence of genetic blood disorder in the region is likely to increase the demand for coagulation analyzer in the market. The prevalence of genetic blood disorders (sickle cell anemia and thalassemia) varies among the different regions of the Kingdom of Saudi Arabia. The highest rates are recorded in the eastern and southern regions, while the rates are low in the central and northern regions of the Kingdom. Additionally, as per the Dubai Health Authority, in 2019, there were about 2,000 people with thalassaemia in the UAE. Further, the government-run Thalassaemia Centre in Dubai had around 850 patients and of which 450 were critical ones who needed regular blood transfusions. Additionally, as per the World Federation of Hemophilia, in South Africa, in 2019, ~24.6/100,000 males had hemophilia A and 5.0/100,000 males had hemophilia B. also, the prevalence of Von Willebrand Disease (VWD) with bleeding symptoms to primary care physicians appears to be approximately 1 in 1,000.

South Africa faces a chronic cardiovascular disease burden, including high rates of hypertension and cardiac arrest. South Africa is experiencing an increasing burden of cardiovascular diseases, including coronary heart disease (CHD) and stroke. According to WHO, it is estimated that the rate of premature death due to CVD amongst South African adults is projected to increase by 41% between 2000 and 2030. Moreover, in South Africa stroke is a leading cause of death and disability. An increase in the burden of stroke is expected as the population is experiencing a rapid epidemiological transition with increased exposure to and development of stroke risk factors, together with the aging of the population. Healthcare facilities in South Africa are developing and adopting the latest technologies to offer better treatments and diagnoses.

Although the region remains highly exposed to political uncertainty, medical device exports will gain from accelerated economic growth in Sub-Saharan Africa, which will be aided by increased commodity prices and improved investor enthusiasm. In Sub-Saharan Africa, South Africa is the key business center for the medical device industry. A large percentage of medical device and lab equipment exports go to other African countries, with 12 African countries among the top 20 export destinations. Thus, owing to the factors mentioned above, the country is expected to provide an opportunistic scenario for coagulation analyzers market growth in South Africa.

In addition, development in technology, healthcare infrastructure has increased the use of online distribution channels for buying diagnostic devices. The other factors, such as increasing incidences of peripheral artery disease, and rising healthcare expenditure, are likely to lead to the growth of the market during the forecast period. In addition, the growing investment in the healthcare industry is expected to enhance market growth significantly.

Middle East & Africa Coagulation Analyzers Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Coagulation Analyzers Market Segmentation

The Middle East & Africa coagulation analyzers market is segmented into product, test, technology, end users, and country.

Based on product, the Middle East & Africa coagulation analyzers market is segmented into clinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory analyzers segment held the larger Middle East & Africa coagulation analyzers market share in 2022.

Based on test, the Middle East & Africa coagulation analyzers market is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimer testing, platelet function tests, anti-factor xa tests, heparin and protamine dose response tests for act, and others. The prothrombin time testing segment held the largest Middle East & Africa coagulation analyzers market share in 2022.

Based on technology, the Middle East & Africa coagulation analyzers market is segmented into optical technology, mechanical technology, electrochemical technology, and other technologies . The optical technology segment held the largest Middle East & Africa coagulation analyzers market share in 2022.

Based on end users, the Middle East & Africa coagulation analyzers market is segmented into hospitals, clinical laboratories, point-of-care testing, and others . The clinical laboratories segment held the largest Middle East & Africa coagulation analyzers market share in 2022.

Based on country, the Middle East & Africa coagulation analyzers market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. The Saudi Arabia dominated the Middle East & Africa coagulation analyzers market share in 2022.

Abbott Laboratories; Danaher Corp; F. Hoffmann-La Roche Ltd; Horiba Ltd.; Nihon Kohden Corp; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Sysmex Corporation; and Thermo Fisher Scientific Inc are the leading companies operating in the Middle East & Africa coagulation analyzers market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa coagulation analyzers market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa coagulation analyzers market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution